Parschauer Karah Herdman sold $47K of RARE

Parschauer Karah Herdman (EVP and Chief Legal Officer) sold 1,899 shares of Ultragenyx Pharmaceutical Inc. (RARE) at $24.62 on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Parschauer Karah Herdman
Published Jun 15, 2026, 10:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 10:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RARE
Neutral
high confidence
Mentioned
$RARE
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RARENeutralLow
01

Why it matters

The only new information is the officer’s sale details (shares, price, post-transaction holdings) under a pre-arranged 10b5-1 plan; no new company fundamentals are disclosed.

02

Market read

Traders may log the insider sale as a data point, but it is not a catalyst for repricing absent other news.

03

What to watch

The filing does not state motives; without context on prior insider activity frequency/size, interpreting it as bearish is speculative.

Relevance 2/10Novelty 5/10Timing: Filed same day (2026-06-15) for an insider sale executed 2026-06-15.

Background

The article is an SEC Form 4 insider transaction disclosure (open-market sale) for Ultragenyx Pharmaceutical Inc.

Company-level read

Ticker impact

$RARENeutralHigh confidence
Context

Ultragenyx (RARE) disclosed an EVP/Chief Legal Officer open-market sale of 1,899 shares at $24.62 on a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely noise unless paired with other company-specific news.

Evidence & confidence

Form 4 shows a small, pre-planned open-market sale by an officer; the filing provides no new operational, clinical, or regulatory information.

Market effects

Minimal—single insider transaction without accompanying biotech catalyst does not materially change sector risk.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated or unusually timed sales can coincide with internal risk perceptions; traders may watch for follow-on filings.

Key entities

  • Ultragenyx Pharmaceutical Inc.

    RARE, subject of the Form 4 insider transaction disclosure.

  • Parschauer Karah Herdman

    EVP and Chief Legal Officer who sold 1,899 shares via an open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RAREMed

Ultragenyx Pharmaceutical Inc (RARE) Q3 2026 Earnings Call Highlights: Gene Therapy

Ultragenyx Pharmaceutical Inc (RARE) discontinued two gene therapy programs (GTX-102 and UX701) due to efficacy and trial advancement issues. The company is restructuring, cutting 20% of its workforce. The future of setrusumab for osteogenesis imperfecta is uncertain pending FDA discussions. R&D spending for 2027 is guided at less than $350 million, with a focus on commercial products. The company faces potential competition in the Sanfilippo syndrome type A market.

$RAREHighAI 8/10

Ultragenyx (RARE) Q3 2026 Earnings Call Transcript

Ultragenyx (RARE) reported Q3 2026 earnings, highlighting FDA approvals for GENGLYCOS and FAYUVI, two new gene therapies. The company also announced setbacks in clinical trials for GTX-102 and UX701, leading to program terminations and workforce reductions. Revenue guidance for 2026 was reaffirmed at $730M-$760M, with profitability expected in 2027. The company aims to reduce expenses by 50% by 2027.